Lumenis Launches Ocular Surface Care Guide

Clinical Report: Lumenis Launches Ocular Surface Care Guide

Overview

Lumenis introduced “Preventing 20/Unhappy: A Field Guide for Cataract and Refractive Surgeons” at the 2026 American Academy of Ophthalmology annual meeting. The guide addresses clinical care and practice implementation, including screening, treatment planning, patient communication, postoperative care, and workflow integration.

Background

Ocular surface disease can contribute to the “unhappy 20/20 patient,” according to the article. The guide is intended to help cataract and refractive surgeons identify and manage ocular surface disease across the surgical journey. Its clinical section covers preoperative screening, treatment selection, patient conversations, and postoperative care. Its implementation section addresses demonstrating the value of care, assembling a team, and gaining staff buy-in.

Data Highlights

Guide element	Details reported
Launch	Unveiled at the 2026 American Academy of Ophthalmology annual meeting in New Orleans
Structure	Two parts: “The Read” (clinical care) and “The Rollout” (practice implementation)
Contributors and evidence	Insights from five cataract and refractive surgeons and findings from six studies
Clinical tools	Six tear-out tools designed for clinical use
Named treatment option	OptiLIGHT, an intense pulsed light device FDA-approved for dry eye management due to meibomian gland dysfunction

Key Findings

Lumenis said the field guide combines current research, clinical insights, and practical strategies for incorporating ocular surface care into existing workflows.
“The Read” covers preoperative screening, matching treatment to disease, patient conversations, and postoperative care.
“The Rollout” addresses demonstrating the value of ocular surface care, assembling an appropriate team, and gaining staff buy-in.
The guide draws on insights from Christopher Starr, MD, FACS; Preeya Gupta, MD; Brett Levinson, MD; Shareen Greenbaum, MD; and Eric Gershenbaum, MD, as well as findings from six studies.
It includes six tear-out tools and guidance on treatment planning, matching treatment to disease severity, and determining when a patient is ready for surgery.
Related source material describes OptiLight as an IPL technology authorized for improving signs of dry eye disease due to meibomian gland dysfunction; its clinical trial reportedly showed improvement in TBUT, meibum quality, and meibomian gland expressibility.

Clinical Implications

The guide presents ocular surface care as part of the cataract and refractive surgery workflow, from preoperative screening through postoperative care. It also provides practice-implementation material and clinical tools; the source does not report outcomes from use of the guide itself.

Conclusion

The Lumenis field guide combines clinical and practice-implementation content for ocular surface care in cataract and refractive surgery. Its stated scope includes screening, treatment planning, patient communication, and workflow integration.